Onyx Pharmaceuticals completed patient enrollment for a Phase III study comparing the efficacy of multiple myeloma drug Kyprolis, or carfilzomib, with low dose steroids plus optional cyclophosphamide in patients who have received at least three other therapies. The study of about 300 patients will support regulatory applications for Kyprolis.